Regulation of RAD51 at the Transcriptional and Functional Levels: What Prospects for Cancer Therapy?

Esin Orhan 1, Carolina Velazquez 2, Imene Tabet 1, Claude Sardet 1 and Charles Theillet 1,2,*

Abstract: The RAD51 recombinase is a critical effector of Homologous Recombination (HR), which is an essential DNA repair mechanism for double-strand breaks. The RAD51 protein is recruited onto the DNA break by BRCA2 and forms homopolymeric filaments that invade the homologous chromatid and use it as a template for repair. RAD51 filaments are detectable by immunofluorescence as distinct foci in the cell nucleus, and their presence is a read out of HR proficiency. RAD51 is an essential gene, protecting cells from genetic instability. Its expression is low and tightly regulated in normal cells and, contrastingly, elevated in a large fraction of cancers, where its level of expression and activity have been linked with sensitivity to genotoxic treatment. In particular, BRCA-deficient tumors show reduced or obliterated RAD51 foci formation and increased sensitivity to platinum salt or PARP inhibitors. However, resistance to treatment sets in rapidly and is frequently based on a complete or partial restoration of RAD51 foci formation. Consequently, RAD51 could be a highly valuable therapeutic target. Here, we review the multiple levels of regulation of RAD51 expression and function and explore potential therapeutic leads.

Keywords: RAD51; homologous recombination; DNA repair; genomic instability; DNA break; cancer therapy

1. Introduction

DNA damage inflicted by exogenous or endogenous factors such as oxidized radicals, ultra violet (UV) light, ionizing radiation (IR) or genotoxic chemicals are a constant threat to genome integrity. Complex and efficient DNA repair mechanisms preventing the transmission of genetic errors to the progeny are already present in bacteria and have evolved in complexity and specificity in higher eukaryotes. Deficiency in one of the multiple repair mechanisms inevitably results in the accumulation of mutations. DNA repair mechanisms are highly specialized according to the type of damage inflicted. In case of DNA breaks, mechanisms depend on the nature of the break (single or double-strand break), as well as on the cell cycle phase. Unrepaired double-strand breaks (DSB) are
highly toxic because they open the door to illegitimate chromosomal rearrangements and can lead to cancer [1]. To keep DNA integrity and stability, cells need to accurately repair these lesions.

Principal DSB repair mechanisms are non-homologous end joining (NHEJ) repair and homologous recombination (HR) [2]. NHEJ is based on minimal homology of the sequences around the break site in order to ligate the DNA ends. NHEJ is considered an error-prone mechanism that is active throughout the whole cell cycle. During S and G2 phases, HR is activated and competes with NHEJ [3]. Because HR uses the sister chromatid as a template, it is more accurate and avoids misalignment and illegitimate rearrangements that are a risk with NHEJ [4]. Furthermore, DSBs are more susceptible to occurring during the S phase, because of replication fork collapse. For these reasons, HR repair is essential for the integrity of the genome and cell survival. In case of HR deficiency, cells become vulnerable to DSB-induced genome instability [5,6].

When a DSB occurs, the DNA-damage sensors Ataxia-Telangiectasia-Mutated (ATM) and Ataxia Telangiectasia and Rad3-related (ATR) kinases phosphorylate Histone H2AX [7,8]. After this initial signal, DNA repair proteins are recruited to the break site. During the G1 phase of the cell cycle, TP53-Binding Protein (TP53BP1, also called 53BP1) and the shielding complex are recruited at the break site and allow for the recruitment of NHEJ actors, such as DNA-dependent Protein Kinase catalytic subunit (DNA-PKcs), KU70/80, XRCC4 and LIG4 [9,10]. During the S/G2 phases of the cell cycle, Breast Cancer 1 (BRCA1) is phosphorylated and activated by the Cyclin Dependent Kinase 1 (CDK1) [11] and, in the presence of DSB, BRCA1 is also phosphorylated by Checkpoint Kinase 2 (CHK2) that signals the start of the HR repair (HRR) cascade [12]. BRCA1 binds to CtBP-interacting protein (CtIP) that competitively removes 53BP1 from the DSB site and engages HRR [13,14]. CtIP recruits the MRN exonuclease complex which resects the DNA from 5’ to 3’, leaving long 3’ single-strand DNA (ssDNA) overhangs on either side of the DSB [15]. The ssDNA overhangs are rapidly coated and protected by Replication Protein A (RPA). BRCA1 recruits BRCA2 at the break site together with the bridge protein Partner and Localizer of BRCA2 (PALB2). Then, BRCA2 recruits the RAD51 recombinase, which is a crucial protein for the HR to occur. The RAD51 protein forms homopolymeric filaments around the ssDNA and removes RPA. Then, it proceeds to the invasion of the sister chromatid and searches for the matching homologous sequence (Figure 1) [16].
Figure 1. Representation of DNA double-strand break repair choice in the S/G2 phase between homologous recombination non-homologous end joining. The scheme details the steps leading homologous strand invasion and D loop formation. Step 1: 3' end resection by the MRN complex, RPA loading to protect single-strand DNA (ssDNA) from degradation. Step 2: BRCA2 is recruited by BRCA1/PALB2 and loads RAD51 onto the ssDNA overhangs and RPA is dislodged. Step 3: formation of the RAD51 Homopolymeric filament which wind around the ssDNA. Step 4: invasion of the homologous chromatid and search for homology in view of recombination and repair.

The RAD51 protein is, thus, key for the DNA-strand exchange steps, which HRR is dependent on. RAD51 belongs to the RAD51 protein family that is characterized by a ~230 amino acid domain containing two ATPase motifs called Walker A and Walker B [17]. Human RAD51 actively binds to ssDNA via its N-terminal portion and mediates HR between homologous DNA strands (Figure 2) [18]. RAD51 can be activated by several post-translational modifications, which control its activity at different steps of HRR [19]. We will describe these processes in detail.
RAD51 also plays a role in the repair and re-start of the stalled DNA replication forks, which, in the absence of repair, collapse and leave long stretches of unprotected ssDNA leading to DSB. One of the mechanisms to protect stalled replication forks is replication fork reversal, in which RAD51 is critical [20]. While in normal cells fork reversal is finely tuned to avoid excessive recombination, cancer cells treated with genotoxic agents are challenged with a high number of stalled forks that can overwhelm DNA repair. Thus, elevated levels of RAD51 expression could act as a safeguard to avoid massive fork collapse and protect cancer cells from the accumulation of DNA breaks.

In normal human cells, the expression and activity of RAD51 are tightly controlled in order to avoid aberrant DNA recombination [21]. It is of note that RAD51 expression is strongly increased in breast, thyroid or pancreatic cancer [22–24] and that its overexpression is strongly correlated with poor prognosis [25,26]. Over-activated HRR has been proposed to increase the genetic plasticity of cancer cells due to elevated recombination [21,27]. It is also thought to increase the capacity to repair DNA breaks and, hence, protect cells from DNA-damaging treatments. Indeed, elevated RAD51 expression has been correlated with resistance to chemotherapy [28,29]. Conversely, BRCA-deficient ovarian cancers, which are HR-deficient, show increased sensitivity to platinum salts and Poly (ADP-ribose) polymerase inhibitors (PARPi) [30]. However, resistance to treatment occurs quickly and, in the case of PARPi, arises mainly by restoring HRR despite BRCA-deficiency. In some studies, restored HRR is monitored by the presence of RAD51 foci in nuclei after treatment-induced DNA damage [31]. This led some authors to propose the use of RAD51 expression or foci detection as a predicting biomarker of HR proficiency to orient the choice of treatments.

The need of alternative treatments for cancer patients that do not respond or develop resistance to DNA-damage-inducing treatments has become evident. RAD51 downregulation has been proposed as a strategy to overcome drug resistance [29]. Thus, better apprehension of RAD51 activity and regulation could lead to new therapeutic strategies for resistant tumors. Several inhibitors of potential RAD51 regulators, either alone or in combination with DNA-damaging agents, have been tested in clinical trials listed in the supplementary table (Table S1). In this review, we highlight the importance of RAD51 regulators at the transcriptional and post-translational levels and potential implications for novel treatment strategies. We discuss the clinical significance of RAD51 as a biomarker for HR capacity.

2. Regulation of RAD51 Expression

Transcription factors that regulate RAD51 transcription could, thus, be key in the response of cancer cells to DNA-damaging treatments (Figure 3).
2.1. Transcriptional Control of RAD51

2.1.1. Cyclin Dependent Kinases

Cyclin-dependent kinases (CDK) have been proposed to play a role in the transcriptional regulation of RAD51. CDKs are a large family of genes primarily known to regulate cell transition from one cell cycle phase to the next. However, CDK7-13 have been shown to act as key regulators of transcription by way of phosphorylation of the C-terminal domain (CTD) of RNA polymerase II at different serine residues and promote the recruitment of factors necessary for full initiation and elongation of transcripts [32]. During gene transcription by RNA pol II, CDK7, a subunit of TFIH, phosphorylates Ser5 and activates transcription initiation, whereas CDK9, which forms the pTEF complex with Cyclin T, phosphorylates Ser2 and catalyzes the elongation of the transcripts [33,34]. Interestingly, genetic knockdown or pharmacological inhibition of CDK9 revealed that highly transcribed genes associated with super-enhancers, such as oncogenes or anti-apoptotic genes, were preferentially impacted in cancer cells [34].

Another actively studied CTD Ser2 kinase, whose role was initially discovered in Drosophila, is CDK12 [35]. CDK12, which associates with cyclin K (CCNK), was also shown to regulate transcription elongation. Remarkably, the genetic depletion or pharmacological inhibition of CDK12 appeared to mainly affect long genes comprising multiple exons. This particularity has been attributed to the fact that CDK12 suppresses intronic polyadenylation, thus allowing for the full-length transcription of these long genes [36–38]. CDK13, which has strong sequence homology with CDK12, has been predicted to share a similar role in pre-mRNA processing [36].

CDK12 and its homolog, CDK13, have been recently proposed to regulate specifically the expression of DNA damage response genes (Table 1) [36,39,40]. Indeed, inhibition of CDK12 either by a drug or by small interfering RNAs (siRNAs) was shown to selectively decrease the expression of DNA damage response genes, such as BRCA1, ATM, FANCD2 and FANCI, possibly because these are large genes with multiple exons [36,39]. Interestingly, Querada and coworkers (2019) suggested that RAD51 expression could be regulated by CDK13, while BRCA1, FANCD2 and ATM transcription was dependent on CDK12 [40]. It thus seems that the knockdown of CDK12/13 affects the transcription of a smaller set of genes compared with the knockdown of CDK9, and it is not yet entirely clear how much both lists overlap. However, the increasing evidence of CDK12 mutations in prostate, triple-negative breast and more so in ovarian cancer has put the focus on this gene that is not considered to belong to the HR pathway per se [41–43]. Indeed, in The Cancer Genome Atlas (TCGA) dataset, 3% of high-grade serous ovarian cancer harbored a CDK12 mutation, an incidence similar to that observed for BRCA1 and BRCA2 (3.5 and
3.2%, respectively) [44]. Furthermore, consistent with a role of CDK12 in the regulation of HR genes, a combination of mechanistic studies with clinical evidence indicated that CDK12-driven transcription of HR genes is crucial for genome stability [45–48]. Hence, CDK12 could be a target of choice to exploit cancer vulnerability associated with DNA damage. Although further understanding of the impact and specificity of CDK inhibition on HR gene expression and activity is needed, it can be hypothesized that the use of selective inhibitors of these kinases could be a strategy of choice to sensitize cancer cells to genotoxic treatment [47]. This is supported by a number of studies on cell lines and pre-clinical models, showing that PARP-inhibitor (PARP-i) administration combined with a CDK12/13 inhibitor (CDK12-i), such as Dinaciclib or SR-4835, is synergistic compared with PARP-inhibitor alone [40, 48–50]. Furthermore, the PARP-i/CDK12-i combination has been suggested to reverse acquired PARP-i resistance [48]. An ongoing clinical trial involving 63 triple-negative breast patients treated with Dinaciclib combined with Veliparib will give us the first clues on the benefits (efficacy and tolerability) of this regimen (Table S1) [50].

### Table 1. Regulators of RAD51 at the transcriptional and post-translational levels. Abbreviation: RNA polymerase II (RNA pol II).

| Regulator of RAD51 | Function | Level of regulation | Effect on RAD51 | Drug target |
|--------------------|----------|---------------------|-----------------|-------------|
| CDK12/CDK13        | RNA pol II regulator | mRNA expression | Activator | Yes |
| E2F1               | Transcription Factor | mRNA expression | Activator | No |
| E2F4               | Transcription Factor | mRNA expression | Repressor | No |
| E2F7               | Transcription Factor | mRNA expression | Repressor | No |
| FOXM1              | Transcription Factor | mRNA expression | Activator | No |
| EGR1               | Transcription Factor | mRNA expression | Activator | No |
| P53                | Transcription Factor | mRNA expression | Repressor | No |
| BRD4               | Transcription Activator | mRNA expression | Activator | Yes |
| CHD4               | Nucleosome Remodeler | mRNA expression | Activator | No |
| PLK1               | Kinase | Post-translational | Activator | Yes |
| CK2                | Kinase | Post-translational | Activator | Yes |
| CHK1               | Kinase | Post-translational | Activator | Yes |
| UCHL3              | Deubiquitinatnsase | Post-translational | Activator | No |
| FBH1               | Ubiquitin ligase | Post-translational | Repressor | No |
| FBX05              | Ubiquitin ligase | Post-translational | Repressor | No |
| RFWD3              | Ubiquitin ligase | Post-translational | Repressor | No |
| RAD51C             | RAD51 Cofactor | Homofilament Loading/stabilisation | Activator | No |
| RAD51B             | RAD51 Cofactor | Homofilament Loading | Activator | No |
| RAD51D             | RAD51 Cofactor | Homofilament Loading | Activator | No |
| XRCC1              | RAD51 Cofactor | Homofilament stabilisation | Activator | No |
| XRCC2              | RAD51 Cofactor | Homofilament Loading | Activator | No |
| SWSAP1             | RAD51 Cofactor | Homofilament stabilisation | Activator | No |
| PARI               | DNA Helicase | Homofilament stabilisation | Repressor | No |
| BLM                | DNA Helicase | Homofilament stabilisation | Repressor | No |

#### 2.1.2. Member of the E2F Transcription Factor Family

Other documented transcription regulators of RAD51 are E2F family members, which are central gatekeepers of cell cycle progression and survival. Their transcriptional activity is regulated by the binding of retinoblastoma (RB) protein and pocket proteins, p107 and p130 [51, 52]. Noticeably, E2F1, E2F4 or E2F7 are activated and stabilized upon DNA damage, possibly by way of phosphorylation by ATM, ATR and CHK2 [53, 54]. Elevated E2F1 expression levels have been associated with poor prognosis in non-small cell lung carcinomas and gastrointestinal carcinomas [55, 56]. In colon cancer cell models, knockdown of E2F1 was correlated with loss of RAD51 expression and RAD51-dependent DSB repair [57]; furthermore, E2F1 and BRIT1 (MCPH1) were shown to form a complex
that activates the transcription of BRCA1, CHK1, p73 and CASP7 [58]. These data strongly suggest that E2F1 could have a role in both activating the transcription of HR genes and their recruitment to DSB.

E2F4 could also play a role in the transcriptional regulation of RAD51. Under hypoxic conditions, E2F4 binds to p130 and represses BRCA1 and RAD51 transcription [59]. The E2F4/p130 driven repression of HR genes could be one of the mechanisms explaining genetic instability in hypoxic cells, a liability that could be exploited to design cancer therapy strategies.

E2F7 has been shown to orchestrate transcription under chemotherapy-induced DNA damage. In such conditions, it binds to the promoter of RAD51, BARD1, CtIP, BRIP1 and FANCI and represses their expression. Depletion of E2F7 in U2OS human osteosarcoma cells resulted in increased expression of DNA repair pathway genes, enhanced HRR and replication fork stability [60]. In BRCA2-deficient cells, loss of E2F7 favored resistance to the PARPi Olaparib [61].

Finally, we must mention that CDK2 and CDK4/6 are direct regulators of the transcriptional activity of the E2F-Pocket protein complexes [62,63], adding another, yet unexplored level of complexity to the aforementioned connections between CDKs and HR genes. Taken together, a better apprehension of the mechanisms governing DNA repair gene transcriptional regulation of the different E2F family members could open novel therapeutic avenues in cancer.

2.1.3. Other Transcription Factors

The transcription factor FOXM1 has been suggested to transactivate RAD51 binding directly to its promoter and mediating resistance to chemotherapy [64]. FOXM1 is a pro-oncogenic transcription factor that is overexpressed in glioblastoma multiforme (GBM) and correlated with increased RAD51 expression. FOXM1 inhibition has been proposed as a potential therapeutic strategy in GBM.

Other identified RAD51 transcription regulators comprise EGR1, as an activator, and p53 as a repressor [65,66]. Interestingly, while the normal function of phosphorylated p53 is to repress RAD51 expression, the p53 contact mutant R280K loses this ability and does not reduce DNA-damage-induced RAD51 foci, possibly explaining the resistance to chemotherapy of p53-mutated cancers.

2.2. Chromatin-Mediated Regulation of RAD51 Gene Expression

The members of the Bromodomains and Extraterminal (BET) family, comprising 4 genes BRD2, BRD3, BRD4 and BRD6 (specific to testis and ovary), are important transcriptional and epigenetic regulators that play key roles in embryogenesis and cancer [67]. They harbor two evolutionary conserved tandem bromodomains (BD1, BD2) and an extraterminal domain (ET) [68]. The BD domains bind to acetyl-lysine residues of DNA-associated proteins, such as histones or transcription factors [69]. The affinity of BRD proteins to multi-acetylated histones is high in general, to the point that BRD4 is considered one of the most abundant proteins on transcriptionally active chromatin. Originally characterized as a key regulator of gene expression during the M to G1 transition [70], BRD4 was found to promote self-renewal of embryonic stem cells [71]. More recently, it was reported to be abundant at enhancer regions and particularly at super-enhancers (SE), which gather several enhancers of highly active genes, including HR genes such as BRCA1 and RAD51 [72,73].

The current model proposes that BRD4 stabilizes transcription factors at enhancers and activates transcription. Through its ET domain, BRD4 binds to various histone modifiers such as the demethylase JMJD6, the methyltransferase NSD3 and the SWIF/SNF enzyme. The recent discovery that super-enhancers in cancer cells are associated with major oncogenes, such as the MYC gene, has identified the BET protein family as a valuable drug target in cancer and fostered the development of several inhibitors (Table 2).
Table 2. Molecules targeting potential regulators of RAD51 expression and function tested in clinical trials.

| Drug               | Target | Trial phase | Trial Status | Results                                                                 | Trial number |
|--------------------|--------|-------------|--------------|--------------------------------------------------------------------------|--------------|
| CYT-0851           | RAD51  | Phase 1/2   | On going     | Tolerable in combination with veliparib Anti-tumor activity is limited in non-BRCA carriers | NCT03997968 |
| Dinaciclib         | Inhibition of multiple CDKs | Phase 1 | On going | Tolerable in combination with veliparib Anti-tumor activity is limited in non-BRCA carriers | NCT01434316 |
| INCB054329         | Inhibition of BET proteins | Phase 1/2 | Completed | 30% Stable disease 43% Progressive disease | NCT02431260 |
| SYHA1801           | BRD4   | Phase 1     | On going     | Not reported                                                             | NCT04309968 |
| PLX51107           | BRD4   | Phase 1     | Completed    | Tolerable except for patients with extensive hepatic metastasis          | NCT04022785 |
| BMS-986158         | Inhibition of BET proteins | Phase 1 | On going     | Not reported                                                             | NCT03936465 |
| AZD5153            | BRD4   | Phase 1     | Completed    | Tolerable                                                                | NCT03205176 |
| GSK525762          | Inhibition of BET proteins | Phase 1 | Completed | Manageable tolerability                                                  | NCT01587703 |
| Volasertib         | PLK1   | Phase 3     | Completed    | Did not meet primary objective in combination with cytarabine           | NCT01728176 |
| Onvansertib        | PLK1   | Phase 2     | On going     | Not reported                                                             | NCT03414034 |
| TAK-960            | PLK1   | Phase 1     | Completed    | Terminated due to lack of efficacy                                        | NCT01179399 |
| CYC140             | PLK1   | Phase 1     | Completed    | Not reported                                                             | NCT03884829 |
| NMS-1286937        | PLK1   | Phase 1     | Completed    | Tolerable                                                                | NCT01014429 |
| CX-4945            | CK2    | Phase 1/2   | Completed    | Not reported                                                             | NCT02128282 |
| MK-8776            | CHK1   | Phase 2     | Completed    | Similar result as control arm                                           | NCT01870596 |
| SRA737             | CHK1   | Phase 1/2   | Completed    | Tolerable                                                                | NCT02797964 |
|                   | CHK1   | Phase 1/2   | Completed    | Tolerable                                                                | NCT02797977 |
| LY2603618          | CHK1   | Phase 1/2   | Completed    | Toxicity when combined with pemetrexed+Cisplatin                        | NCT01139775 |
| Prexasertib        | CHK1   | Phase 2     | On going     | Tolerable, only modest activity in BRCA mutant HGSOC patients            | NCT02203513 |

However, BRD4 is also an important actor of the mediator complex, which modulates RNA pol II activity, at least in part through the recruitment of the P-TEFb (CCNT1/CDK9) elongation factor. Hence, the inhibition of BRD4 could have effects similar to those of CDK9 inhibition [68,74,75]. Indeed, several studies proposed that the depletion or pharmacological inhibition of BRD4 directly impacted the expression of HR genes, such as RAD51, BRCA1 and BRIP1, and enhanced the sensitivity of cancer cells to PARP inhibitors [72,73]. These results were consolidated by chromatin immunoprecipitation (ChIP) results showing that BRD4-binding to the RAD51 promoter was indeed lost in breast cancer cell lines treated with the BRD4 inhibitor JQ1 and correlated with the loss of RAD51 mRNA expression [73]. These data were corroborated by a study on ovarian cancer cell line models showing that BET inhibitor INCB0544329 synergized with the PARPi Olaparib and resulted in reduced expression of BRCA1 [76]. Altogether, these data suggest that BET
inhibitors and more specifically BRD4 inhibitors are interesting leads to induce BRCA-deficiency in cancer cells. Thus, results of ongoing clinical trials using BET-i should be followed with attention.

CHD4 (chromodomain helicase DNA-binding protein 4) is another modifier that has been proposed to impinge on the expression of HR genes. CHD4 is a highly conserved ATPase forming the core subunit of the nucleosome remodeling NuRD complex. NuRD acts both as a transcription repressor and transcription activator and has been shown to play a role in DNA repair [77]. Indeed, CHD4 was shown to be necessary for the recruitment of BRCA1 upon DNA damage in U2OS cells [78,79]. Furthermore, in glioblastoma cells, CHD4 was suggested to regulate RAD51 expression directly by binding to the RAD51 promoter and increase the acetylation of histone H3 at lysine 9 (H3K9Ac) [80], possibly through an interaction with the CBP and p300 co-activators. In line with this model, these acetyl-transferases have been shown to acetylate histones H3 and H4 at the RAD51 and BRCA1 promoters in H1299 human lung cancer cells [81], and CHD4 was shown to interact with p300 in a context of DNA damage [82]. However, it is not yet fully clear whether the CHD4/p300 interaction is critical for RAD51 upregulation or whether it may play a role in the resistance of cancer cells to DNA-damaging treatment.

3. Post-Translational Regulation of RAD51

Once RAD51 is transcribed and translated, its functions are orchestrated by post-translational modifications such as phosphorylation and ubiquitination on specific amino acids (Figure 4). A better understanding of these events could give leverage to modulate its activation or stabilization with a potential impact on anti-cancer treatment strategies.

Figure 4. Post-translational modifications that impinge on RAD51 function. (A) Modifications leading to the activation and loading of RAD51: phosphorylation cascade at Ser14 and Thr13 by PLK1 and CK2, phosphorylation at Thr307/309 by CHK1, ubiquitination at Lys56/57/63 by UCHL3. (B) Modifications leading to the inactivation of RAD51: ubiquitination at Lys58/64 by FBH1, polyubiquitination by FBK05 or RFWD3 leading to the degradation of RAD51 by the proteasome. Blue bubbles (P) represent phosphorylation, red bubbles (Ub) represent ubiquitination.

3.1. Post-Translational Modifications Leading to Activation of RAD51

Phosphorylation by Polo-like kinase 1 (PLK1) and Casein Kinase 2 (CK2): In irradiated HeLa cells, RAD51 is first phosphorylated at Ser14 by PLK1, which primes for the phosphorylation at Thr13 by CK2 [83]. Since RAD51 binding with the FHA domain of NBS1 requires the phosphorylation at both S14 and T13, these sequential phosphorylations could represent important activating steps [83]. Indeed, the RAD51/NBS1 interactions are essential for RAD51 loading onto DSB sites in a BRCA2-independent manner, possibly promoting resistance to IR and PARPi in BRCA2-mutated HeLa cells. It is tempting to speculate that a combined therapy using inhibitors against both PLK1 and PARP or against CK2 and PARP may be an effective approach to improve the prognosis of BRCA-defective cancers.
However, it is unclear whether and through which signals PLK1 and CK2 are activated in response to DSB [84]. PLK1 overexpression has been associated with resistance to doxorubicin, paclitaxel, metformin and gemcitabine via several mechanisms, such as microtubule rearrangement, p53 inactivation or metabolic changes in cell culture and xenograft models [85]. Additionally, the Ser/Thr protein kinase CK2 is constitutively active and ubiquitously expressed, but its role in the DNA damage response is unclear. CK2 is primarily seen as an essential regulator of transcription, including that of major cancer transcription activators, such as MYC or β-catenin. A number of CK2 inhibitors have been described, some of which made it through preclinical stages. CX-4945 (Silmitasertib), a potent ATP competitor with an excellent selectivity, is one of the most promising. It is currently tested in phase I and II clinical trials in mono therapy or in combination with cisplatin and gemcitabine. The results of these combination trials could be highly revealing [86], and it should be interesting to investigate the role of RAD51 in the response.

Phosphorylation of RAD51 by CHK1: The CHK1 kinase has been proposed to contribute to the formation of RAD51 foci after genotoxic treatment. Attenuation of CHK1 expression by siRNA transfection was shown to strongly reduce RAD51 foci formation upon UV light irradiation, while CHK2 inactivation had no effect [87]. RAD51 foci formation depends on its phosphorylation at T307 and T309, which are consensus CHK1 phosphorylation sites. Accordingly, T307-309 phosphorylation and RAD51 foci formation were reduced in cells treated with a CHK1 inhibitor. The authors determined on human pancreatic cancer and osteosarcoma cell line models that CHK1 inhibition affected the de novo formation of RAD51 oligomers but not their stability [88,89]. Interestingly, the binding and recruitment of RAD51 by BRCA2 appeared to be dependent on its phosphorylation by CHK1 at T307, giving some mechanistic insight into the impact of CHK1 on RAD51 oligomerization [89]. Taken together, we suggest that the treatment of cancer cells with CHK1 inhibitor could not only affect the replication checkpoint, but could also interfere with RAD51 foci formation and, thus, induce HR deficiency. However, most preclinical and clinical trials have focused on the use of CHK1-i to potentiate replication poisons and induce catastrophic replication stress [90–92].

Deubiquitination by UCHL3: UCHL3 is a protease of the deubiquitinating enzyme family that catalyzes the removal of ubiquitin moiety from RAD51. RAD51 deubiquitination by UCHL3 was observed both in vitro and in cellulo and shown to be critical for BRCA2–RAD51 interaction, RAD51 recruitment to DSB sites, foci formation, as well as RAD51-mediated D-loop formation [93]. The key role played by UCHL3 in RAD51 activation is illustrated by the dramatic decrease in HR and PARPi sensitivity in UCHL3-depleted cells [93]. Hence, UCHL3 could be a valuable target to induce pharmacological HR deficiency.

3.2. Post-Translational Modifications Leading to RAD51 Inactivation

Ubiquitination of RAD51: Several factors control the ubiquitin-dependent RAD51 protein stability. These include two F-box domain protein and an RING-type E3 ligase, which appear to act at different time-points. The F-box DNA helicases FBH1 and FBX05 (also called EMII) actively assemble SCF (SKP1-CUL1-F-box protein) complexes that act as E3 ubiquitin ligases and target RAD51 for degradation. FBH1 ubiquitinates RAD51 at K58 and K64, resulting in its accumulation in the cytoplasm and a reduction of HRR efficiency after DSB induction [94–98]. FBX05 (EMI1) was the top-hit of an siRNA screen targeting human F-box genes with the aim to identify mediators of olaparib (PARPi) resistance [99]. In this study, FBX05 was the only F-Box protein to co-immunoprecipitate with RAD51. Its silencing dramatically increased steady state levels of the RAD51 protein and induced the accumulation of RAD51 foci [99].

The RING-type E3 ligase RFWD3 binds to and ubiquitinates RPA2 in DNA-damage-induced foci. It was thus proposed to regulate levels of RPA2 bound to ssDNA [100,101] and to play a role in HR [99]. It was later shown that RFWD3 also promotes the ubiquiti-
nation of RAD51, reducing its binding to ssDNA and increasing its turnover in DNA damage foci [102]. Hence, whereas FHB1 and FBX05 seem to act as global regulators of RAD51 protein levels, RFWD3 appeared to be more specifically involved in the regulation of RAD51 levels bound to ssDNA during the DNA damage or DNA replication stress.

3.3. RAD51 Loading and Stability at DSB Site by Protein–Protein Interactions

As described earlier, RAD51 loading at DSB sites and the subsequent RAD51 homopolymeric-filament assembly, stabilization and timely disassembly are finely tuned steps that determine HR efficiency (Figure 5). A number of interactors and regulators have been identified and more might be discovered in the future.

![Figure 5](image)

**Figure 5.** Intervention of RAD51 cofactors in RAD51 loading and stabilization of the filaments. The BCDX2 intervenes at early stages of RAD51 loading, while CX3 stabilizes the filaments onto the ssDNA.

RAD51 recruitment: In an HR-proficient context, RAD51 is actively recruited by a triprotein complex formed by BRCA1, PALB2 and BRCA2. Of this triad, BRCA2 actively loads RAD51, while the two other partners stabilize the complex. This explains why RAD51 foci formation is reduced or absent in BRCA1 or PALB2 defective cells. However, alternative or safeguard mechanisms have been described to restore RAD51 recruitment in the absence of BRCA1. These range from the loss of expression of 53BP1, the phosphorylation of PALB2 by ATR and the binding of PALB2 by RNF168, which all favor PALB2 activation and accumulation onto DNA damage sites, where it promotes RAD51 recruitment by BRCA2 [103–106]. These observations clearly showed that the intervention of RNF168 could serve as an auxiliary backup mechanism in a BRCA-deficient context [107].

RAD51 paralogs: RAD51 is a highly conserved gene going back to recA in bacteria, which evolved during the early stage of eukaryotic evolution into the RAD51 and DMC1 (meiosis specific genes) subfamilies. In higher eukaryotes, the family comprises seven paralogs, RAD51, RAD51B, RAD51C, RAD51D, XRCC2, XRCC3, and the later identified SWSAP1 [108–110].

The RAD51 paralogs share only 20–30% identity at the protein level with RAD51, essentially in the ATP-binding Walker A and B domains and show comparable similarity to each other [109]. The biological functions of RAD51 paralogs have long been questioned. First, answers came from the yeast that possesses two paralogs, rad55 and rad57,
which form heterodimers that interact with RAD51 and stimulate strand exchange reactions [111]. In higher eukaryotes, genetic studies on chicken cell lines showed that defective RAD51 paralogs were associated with increased sensitivity to DNA-damaging agents, suggesting a role in HR [111–114]. The importance of the RAD51 paralogs was further underlined by genetic studies showing an increased risk of developing breast and/or ovarian cancer in women bearing RAD51C, RAD51D or XRCC2 mutations [115–117]. This association was confirmed in breast and/or ovarian cancer families and cohorts with no known BRCA1 or BRCA2 mutations, leading to the proposition to include RAD51D and RAD51C to the list of genes screened for breast cancer predisposition [118–120].

In 2001, Masson and coworkers showed that the five human paralogs assembled in two distinct complexes: the first one, BCDX2, is formed of RAD51B, RAD51C, RAD51D and XRCC2, while the second one, identified as CX3, was comprised of RAD51C and XRCC3 [121–123]. More recently, SWSAP1, number six of the gang and non-classical RAD51 paralog, was shown to form a heterodimer with SWS1 termed the Shu complex [124–126]. Whereas the RAD51 paralogs are known to promote RAD51-mediated activities, their precise mechanism of action is not yet completely clear. To decipher their respective roles, several groups have performed conditional knock-out studies of the different genes. Using drug sensitivity and RAD51 foci formation as read-outs, they observed phenotypes of variable severity. The strongest impact was observed for RAD51C and RAD51D disruption, whereas RAD51B knock-out only moderately affected HR [127]. The increased impact of RAD51C and RAD51D was explained by the disruption of the CX3 and BCDX2 complexes and associated destabilization of the XRCC3 and XRCC2 proteins. It was also demonstrated that the CX3 and BCDX2 complexes operate at different stages of HR. Both act downstream of BRCA1 and BRCA2 recruitment to damage sites, but BCDX2 acts upstream of RAD51 recruitment, while CX3 has been suggested to intervene after RAD51 homopolymer formation and possibly stabilize them [123,128]. However, results showing that the CX3 complex binds directly to ssDNA suggest that it could also act prior to RAD51 foci formation [122].

SWSAP1: In yeast and worms, disruption of the Shu complex resulted in increased mutagenicity and impaired HR [124,129,130]. Unlike other RAD51 mediators, disruption of the Shu genes primarily impacted on MMS sensitivity and not on other DNA-damaging agents such as IR, hydroxyurea or the Topoisomerase 2 inhibitor etoposide [131]. Consistent with a conserved function of the Shu complex in humans, siRNA depletion of SWS1 and SWSAP1 in human cells resulted in increased MMS sensitivity and reduced RAD51 foci formation [124,125].

PARI: PARI is an UvrD-like helicase-domain containing protein that is recruited on DNA by SUMO-modified PCNA and shown to actively reduce RAD51 nucleofilament formation [132]. Indeed, the knock-down of PARI significantly increased RAD51 foci formation in both basal and DNA-damaging conditions [132]. Hence, PARI has been proposed to act as a negative regulator of HR by disassembling toxic RAD51 nucleofilaments. It is, however, not known whether the disassembly of RAD51 filaments by PARI is associated with a post-translational modification of RAD51.

BLM: the BLM gene codes for a DNA helicase of the RecQ family, which has been shown to interact with RAD51. RAD51 foci formation appeared constitutively activated in BLM-mutated cells and was suppressed by the ectopic expression of functional BLM, suggesting that BLM negatively regulates RAD51 foci formation [133].

4. Pharmacological Inhibition of RAD51

The important role of RAD51 in DNA repair made it an attractive pharmacological target in cancer treatment and has motivated investigators to search for small molecule inhibitors that could disrupt its functions. At least seven compounds antagonizing RAD51 efficiently have been reported.

B02 has been discovered as part of a high-throughput in vitro screening assay scoring for DNA strand exchange. It specifically inhibits human RAD51, but not the E. coli RecA
protein [134]. It disrupted RAD51 binding to DNA, inhibits nucleoprotein filament formation and greatly increases the sensitivity of cancer cells to a wide range of genotoxic drugs, including the DNA cross-linking agents cisplatin and mitomycin C, as well as Topoisomerase 1 (Topotecan) and Topoisomerase 2 (doxorubicin) inhibitors. Further studies have shown interesting effects in combination with MAPK inhibitors on melanoma cells or with proton therapy [135,136]. The therapeutic potential of B02 was confirmed in vivo, where it substantially increased the anticancer potential of cisplatin and notably showed little toxic side effects. Indeed, treated mice showed limited weight loss and no macroscopic modifications of the kidney or liver [136]. These results encouraged the development of a new chemical analogue of B02, B17, which presents greater efficacy than B02 in vitro [137]. However, in vivo evaluation has not been reported yet.

Compounds RI-1 and R7a were isolated on the basis of their capacity to inhibit RAD51 binding to ssDNA [138]. Tested on cell cultures, RI-1 showed potent anti-proliferation activity; however, its short half-life appeared as a strong limit to its in vivo efficacy due to low bio-availability [139].

Compounds IBR2 and derivative IBR120 were isolated on the basis of their capacity to interfere with RAD51 oligomerization and to potentiate its degradation by the proteasome. IBR2 and IBR120 were shown to efficiently inhibit cell growth in a broad set of cancer cell lines [140,141]. In vivo, IBR2 has been tested in single treatment on an imatinib-resistant murine chronic myelogenous leukemia (CML) model, where it significantly prolonged animal survival, without any notable signs of toxicity [140].

Last but not least, the development of compound CYT-0851 is of interest. Firstly, because it is an oral inhibitor that has shown anti-cancer activity on lymphoma as well as the 4T1 mammary tumor in preclinical mouse models [142]. Secondly, because it is, to our knowledge, the only RAD51-i tested in a clinical trial (Table S1).

Altogether, these results suggest that there could be a bright future for small molecule inhibitors of RAD51. However, further tests will be needed to determine in which genetic contexts or tumor types they will prove most effective. Moreover, similarly to other targeted therapies, it is now necessary to identify the best synergistic drug combinations to use with these RAD51 inhibitors. Lastly, induced toxicity and mutagen effects will be critical parameters to take into account for these potent inhibitors.

5. Discussion

Due to its prominent role in DNA double-strand break repair, as well as in the protection and repair of stalled replication forks, RAD51 is a crucial actor in the maintenance of genomic stability. Its expression and activity must be tightly controlled in normal cells. Indeed, insufficient levels of RAD51 could cause an accumulation of unrepaired DNA breaks. Conversely, in excess, RAD51 could provoke hyper-recombination and genetic instability. The question about the consequences and advantages of the strong overexpression of RAD51 in a large fraction of tumors at both the RNA and protein levels remains puzzling. As genomic instability is almost inherent in cancer cells, it is tempting to speculate that over-activation of RAD51 could be part of a compensation mechanism to protect cells from excessive genetic instability. Remarkably, RAD51 is strictly essential for cancer cell survival, as illustrated by the 98% cell lines showing elevated dependency scores for RAD51 gene knock-out (the DepMap database www.depmap.org, accessed on 15th March 2021). In comparison, BRCA1 and BRCA2, two important partners of RAD51, are strictly required for the survival of only 84.5 and 84.7% cell lines, respectively (CERES scores below –0.5). It is of note that BRCA1-mutated cell lines are among those showing the highest dependency scores to RAD51. In fact, a number of BRCA1 or BRCA2-deficient cell models do not show complete obliteration of RAD51 foci when exposed to a genotoxic insult, but rather an attenuated response. This can be explained by maintained or restored recruitment of RAD51 onto DNA lesions even in the absence of BRCA1 or BRCA2 due to compensatory mechanisms which are not yet fully understood. Thus, RAD51 is a crucial DNA
repair actor in a large majority of cancers, notwithstanding their BRCA proficiency or deficiency. Consequently, it has been shown to be an interesting biomarker, as RAD51 expression levels have been proposed to be potentially predictive of resistance to treatment [143,144]. Additionally, assays aimed at determining the capacity of tumor cells to form RAD51 foci when challenged with a DNA-damaging treatment have been proposed as biomarkers of response to PARP-i (NCT04780945) [145]. Furthermore, RAD51 appears as a valuable therapeutic target, especially in tumors prone to accumulate DNA breaks, such as cancers showing strongly rearranged genomes. The design of pharmacological approaches that would efficiently impair or attenuate RAD51 recruitment onto DNA lesions and/or the formation of presynaptic filaments is, in our opinion, the therapeutic strategy of choice, especially in combination with DNA-break-inducing agents. As described above, approaches are aiming at downregulating the mRNA expression of genes belonging to the HR pathway, among which RAD51 is being actively studied. Given the central role of RAD51 in HR, inhibitors that directly target the protein are, as discussed above, interesting leads to be followed (Table S1) [146,147]. Moreover, the future may also bring about further approaches based on inhibitors targeting either enzymes that activate RAD51 or target its cofactors and interfere with homopolymeric filament formation or stabilization. Which approach will be most effective remains undetermined, but we are convinced that targeting RAD51 directly or its cofactors will have great clinical potential in the future.

Supplementary Materials: The following is available online at www.mdpi.com/article/10.3390/cancers13122930/s1, Table S1: Clinical Trials.

Author Contributions: E.O. conceptualized the overall idea for this review, organized the thoughts and designed the backbone of this review. E.O. and C.T. wrote this review. I.T., C.V. and C.S. reviewed and edited this review. All authors have read and agreed to the published version of the manuscript.

Funding: E.O. is currently a doctoral fellow of the Labex Epigenmed. Furthermore, the authors wish to express their gratitude for the support of the SIRIC Montpellier Cancer Grant INCa-DGOS-Inserm_12553 to E.O., I.T. and C.V.

Acknowledgments: Figures are created with BioRender.com

Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations

| Acronym | Description |
|---------|-------------|
| ATM | Ataxia-Telangiectasia Mutated |
| ATR | Ataxia Telangiectasia and Rad3 Related |
| BD | Bromodomain |
| BET | Bromodomains and Extraterminal |
| BRCA1 | Breast Cancer 1 |
| BRCT | BRCA1 Carboxy-Terminus |
| CCNK | Cyclin K |
| CDK | Cyclin-Dependent Kinase |
| ChiP | Chromatin Immunoprecipitation |
| CHD4 | Chromodomain Helicase DNA-binding Protein 4 |
| CK2 | Casein Kinase 2 |
| CML | Chronic Myelogenous Leukemia |
| CTD | C-Terminal Domain |
| ChiP | CtBP-Interacting Protein |
| DNA | Deoxyribonucleic acid (necessary?) |
| DNA-PKcs | DNA-dependent Protein Kinase Catalytic Subunit |
| DSB | Double-Strand Break |
| ET | Extraterminal Domain |
| GBM | Glioblastoma Multiforme |
| H2AX | Histone 2AX |
| HR | Homologous Recombination |
References

1. Bennett, C.B.; Lewis, A.L.; Baldwin, K.K.; Resnick, M.A. Lethality induced by a single site-specific double-strand break in a dispensable yeast plasmid. *Proc. Natl. Acad. Sci. USA* 1993, 90, 5613–5617, doi:10.1073/pnas.90.12.5613.

2. Chapman, J.R.; Taylor, M.R.G.; Boulton, S.J. Playing the end game: DNA double-strand break repair pathway choice. *Mol. Cell* 2012, 47, 497–510, doi:10.1016/j.molcel.2012.07.029.

3. Isono, M.; Niimi, A.; Oike, T.; Hagiwara, Y.; Sato, H.; Sekine, Y.; Isobe, S.-Y.; Obuse, C.; Nishi, R.; et al. BRCA1 directs the repair pathway to homologous recombination by promoting 53BP1 dephosphorylation. *Cell Rep.* 2017, 18, 520–532, doi:10.1016/j.celrep.2016.12.042.

4. Rothkamm, K.; Krüger, I.; Thompson, L.H.; Löbrich, M. Pathways of DNA double-strand break repair during the mammalian cell cycle. *MCB* 2003, 23, 5706–5715, doi:10.1128/MB.23.16.5706-5715.2003.

5. Pöti, A.; Gyergyák, H.; Németh, E.; Rusz, O.; Tóth, S.; Kovácszai, C.; Chen, D.; Szikriszt, B.; Spisák, S.; Takeda, S.; et al. Correlation of homologous recombination deficiency induced mutational signatures with sensitivity to PARP inhibitors and cytotoxic agents. *Genome Biol.* 2019, 20, 240, doi:10.1186/s13059-019-1867-0.

6. Jeggo, P.A.; Geuting, V.; Löbrich, M. The role of homologous recombination in radiation-induced double-strand break repair. *Radiother. Oncol.* 2011, 101, 7–12, doi:10.1016/j.radonc.2011.06.019.

7. Ward, I.M.; Chen, J. Histone H2AX is phosphorylated in an ATR-dependent manner in response to replicational stress. *J. Biol. Chem.* 2001, 276, 47759–47762, doi:10.1074/jbc.C100569200.

8. Burma, S.; Chen, B.P.; Murphy, M.; Kurimasa, A.; Chen, D.J. ATM phosphorylates histone H2AX in response to DNA double-strand breaks. *J. Biol. Chem.* 2001, 276, 42462–42467, doi:10.1074/jbc.C100466200.

9. Ghezraoui, H.; Oliveira, C.; Becker, J.R.; Bilham, K.; Moralli, D.; Anzilotti, C.; Fischer, R.; Deobagkar-Lele, M.; Sanchiz-Calvo, M.; Fueyo-Marcos, E.; et al. 53BP1 cooperation with the REV7–shieldin complex underpins DNA structure-specific NHEJ. *Nature* 2018, 560, 122–127, doi:10.1038/s41586-018-0362-1.

10. Pannunzio, N.R.; Watanabe, G.; Lieber, M.R. Nonhomologous DNA end-joining for repair of DNA double-strand breaks. *J. Biol. Chem.* 2018, 293, 10512–10523, doi:10.1074/jbc.T117.00374.

11. Johnson, N.; Li, Y.-C.; Walton, Z.E.; Cheng, K.A.; Li, D.; Rodig, S.J.; Unitt, C.; Bronson, R.T.; Thomas, H.D.; et al. Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition. *Nat. Med.* 2011, 17, 875–882, doi:10.1038/nm.2377.

12. Zhang, J.; Willers, H.; Feng, Z.; Ghosh, J.C.; Kim, S.; Weaver, D.T.; Chung, J.H.; Powell, S.N.; Xia, F. Chk2 phosphorylation of BRCA1 regulates DNA double-strand break repair. *Mol. Cell. Biol.* 2004, 24, 708–718, doi:10.1128/mcb.24.2.708-718.2004.

13. Yun, M.H.; Him, K. CIP-BRCA1 modulates the choice of DNA double-strand-break repair pathway throughout the cell cycle. *Nature* 2009, 459, 460–463, doi:10.1038/nature07955.

14. Escribano-Díaz, C.; Orthwein, A.; Fradet-Turcotte, A.; Xing, M.; Young, J.T.F.; Tkáč, J.; Cook, M.A.; Rosebrock, A.P.; Munro, M.; Cann, M.D.; et al. A cell cycle-dependent regulatory circuit composed of 53BP1-RIF1 and BRCA1-CtIP controls DNA repair pathway choice. *Mol. Cell* 2013, 49, 872–883, doi:10.1016/j.molcel.2013.01.001.

15. Anand, R.; Ranjha, L.; Cannavo, E.; Cejka, P. Phosphorylated CtIP functions as a co-factor of the MRE11-RAD50-NBS1 endonuclease in DNA end resection. *Mol. Cell* 2016, 64, 940–950, doi:10.1016/j.molcel.2016.10.017.

16. Amunugama, R.; Fishel, R. Homologous Recombination in Eukaryotes. In *Progress in Molecular Biology and Translational Science*; Elsevier: Amsterdam, The Netherlands, 2012; Volume 110, pp. 155–206; ISBN 978-0-12-387665-2.

17. Jiang, S.; Lin, T.; Xie, Q.; Wang, L. Network analysis of RAD51 proteins in metazoans and the evolutionary relationships with their archaeal homologs. *Front. Genet.* 2018, 9, 383, doi:10.3389/fgene.2018.00383.

18. Suzuki, Y.; Chew, M.L.; Suzuki, Y. Role of host-encoded proteins in restriction of retroviral integration. *Front. Microbiol.* 2012, 3, doi:10.3389/fmicb.2012.00227.

19. Ma, C.J.; Gibb, B.; Kwon, Y.; Sung, P.; Greene, E.C. Protein Dynamics of human RPA and RAD51 on SsDNA during assembly and disassembly of the RAD51 filament. *Nucleic Acids Res.* 2017, 45, 749–761, doi:10.1093/nar/gkw1125.
Cancers 2021, 13, 2930

20. Zellweger, R.; Dalcher, D.; Mutreja, K.; Berti, M.; Schmid, J.A.; Herrador, R.; Vindigni, A.; Lopes, M. Rad51-mediated replication fork reversal is a global regulator of genotoxic stress responses in human cells. J. Cell Biol. 2015, 208, 563–579, doi:10.1083/jcb.201406099.

21. Richardson, C.; Stark, J.M.; Ommundsen, M.; Jasim, M. Rad51 overexpression promotes alternative double-strand break repair pathways and genome instability. Oncogene 2004, 23, 546–553, doi:10.1088/sj.onc.1207098.

22. Maacke, H.; Opitz, S.; Jost, K.; Hamdorf, W.; Henning, W.; Krüger, S.; Feller, A.C.; Lopans, A.; Diedrich, K.; Schwinger, E.; et al. Over-expression of wild-type Rad51 correlates with histological grading of invasive ductal breast cancer. Int. J. Cancer 2000, 88, 907–913, doi:10.1002/1097-0215(20002158):6<907::aid-ijc11>3.0.co;2-4.

23. Sarwar, R.; Sheikh, A.K.; Mahajeeen, I.; Bashir, K.; Saeed, S.; Kaya, M.A. Upregulation of RAD51 expression is associated with progression of thyroid carcinoma. Exp. Mol. Pathol. 2017, 102, 446–454, doi:10.1016/j.yexmp.2017.05.001.

24. Zhang, X.; Ma, N.; Yao, W.; Li, S.; Ren, Z. RAD51 is a potential marker for prognosis and regulates cell proliferation in pancreatic cancer. Cancer Cell Int. 2019, 19, 356, doi:10.1186/s12935-019-1077-6.

25. Wiegmans, A.P.; Al-Ejeh, F.; Chee, N.; Yap, P.-Y.; Gorski, J.J.; Da Silva, L.; Bolderson, E.; Chenevix-Trench, G.; Anderson, R.; Simpson, P.T.; et al. Rad51 supports triple negative breast cancer metastasis. Oncotarget 2014, 5, 3261–3272, doi:10.18632/oncotarget.1923.

26. Qiao, G.-B.; Wu, Y.-L.; Yang, X.-N.; Zhong, W.-Z.; Xie, D.; Guan, X.-Y.; Fischer, D.; Kolberg, H.-C.; Kruger, S.; Steuerzbecher, H.-W. High-level expression of Rad51 is an independent prognostic marker of survival in non-small-cell lung cancer patients. Br. J. Cancer 2005, 93, 137–143, doi:10.1038/sj.bjc.6606265.

27. Siaud, N.; Barbera, M.A.; Egashira, A.; Lam, I.; Christ, N.; Schlacher, K.; Xia, B.; Jasim, M. Plasticity of BRCA2 function in homologous recombination: Genetic interactions of the PALB2 and DNA binding domains. PLoS Genet. 2011, 7, e1002409, doi:10.1371/journal.pgen.1002409.

28. Zhao, Q.; Guan, J.; Zhang, Z.; Lv, J.; Wang, Y.; Liu, L.; Zhou, Q.; Mao, W. Inhibition of Rad51 sensitizes breast cancer cells with wild-type PTEN to olaparib. Biomed. Pharmacother. 2017, 94, 165–168, doi:10.1016/j.biopha.2017.07.090.

29. Tsai, M.-S.; Kuo, Y.-H.; Chiu, Y.-F.; Su, Y.-C.; Lin, Y.-W. Down-regulation of Rad51 expression overcomes drug resistance to gemcitabine in non-small-cell lung cancer cells. J. Pharmacol. Exp. Ther. 2010, 335, 830–840, doi:10.1124/jpet.110.173146.

30. Banerjee, S.; Kaye, S.B.; Ashworth, A. Making the best of PARP inhibitors in ovarian cancer. Nat. Rev. Clin. Oncol. 2010, 7, 508–519, doi:10.1038/nrclinonc.2010.116.

31. Meijs, T.G.; Verkaik, N.S.; van Deurzen, C.H.M.; Dubbink, H.J.; den Toom, T.D.; Sledsens, H.F.B.M.; De Hoop, E.O.; Dinjens, W.N.M.; Kanaar, R.; van Gent, D.C.; et al. Direct ex vivo observation of homologous recombination defect reversal after DNA-damaging chemotherapy in patients with metastatic breast cancer. JCO Precis. Oncol. 2019, 3, 1–12, doi:10.1200/PO.18.00268.

32. Harlen, K.M.; Churchman, L.S. The code and beyond: Transcription regulation by the RNA polymerase II carboxy-terminal domain. Nat. Rev. Mol. Cell Biol. 2017, 18, 263–273, doi:10.1038/nrm.2017.10.

33. Eick, D.; Geyer, M. The RNA polymerase II carboxy-terminal domain (CTD) code. Chem Rev. 2013, 113, 8456–8490, doi:10.1021/cr40007lf.

34. Winters, G.E.; Mayer, A.; Buckley, D.L.; Erb, M.A.; Roderick, J.E.; Vittori, S.; Reyes, J.M.; di Iulio, J.; Souza, A.; Ott, C.J.; et al. BET bromodomain proteins function as master elongation transcription factors independent of CDK9 recruitment. Mol. Cell 2017, 67, 5–18.e19, doi:10.1016/j.molcel.2017.06.004.

35. Bartkowiak, B.; Liu, P.; Phatnani, H.P.; Fuda, N.J.; Cooper, J.J.; Price, D.H.; Adelman, K.; Lis, J.T.; Greenleaf, A.L. CDK12 Is a transcription-association-activated CTD kinase, the metazoan ortholog of yeast Ctk1. Genes Dev. 2010, 24, 2303–2316, doi:10.1101/gad.1968210.

36. Blazek, D.; Kohoutek, J.; Bartholomeeusken, K.; Johansen, E.; Hulinkova, P.; Luo, Z.; Cimermancic, P.; Ule, J.; Peterlin, B.M. The Cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes. Genes Dev. 2011, 25, 2158–2172, doi:10.1101/gad.1966231.

37. Bartkowiak, B.; Greenleaf, A.L. Phosphorylation of RNAPII: To P-TEFb or not to P-TEFb? Transcription 2011, 12, 115–119, doi:10.4161/trns.2.3.15004.

38. Liang, K.; Gao, X.; Gilmore, J.M.; Floresen, L.; Washburn, M.P.; Smith, E.; Shilatifard, A. Characterization of human cyclin-dependent kinase 12 (CDK12) and CDK13 complexes in c-terminal domain phosphorylation, gene transcription, and RNA processing. Mol. Cell 2015, 35, 928–938, doi:10.1016/MCB.01426-14.

39. Krajewska, M.; Dries, R.; Grassetti, A.V.; Dust, S.; Gao, Y.; Huang, H.; Sharma, B.; Day, D.S.; Kwiatkowski, N.; Pomaville, M.; et al. CDK12 loss in cancer cells affects DNA damage response genes through premature cleavage and polyadenylation. Nat. Commun. 2019, 10, 1757, doi:10.1038/s41467-019-09703-y.

40. Querida, V.; Bayle, S.; Vena, F.; Frydman, S.M.; Monastyrskyi, A.; Roush, W.R.; Duckett, D.R. Therapeutic targeting of CDK12/CDK13 in triple-negative breast cancer. Cancer Cell 2019, 36, 545–558.e7, doi:10.1016/j.ccell.2019.09.004.

41. Reimers, M.A.; Yip, S.M.; Zhang, L.; Cieslik, M.; Dhawan, M.; Montgomery, B.; Wyatt, A.W.; Chi, K.N.; Small, E.J.; Chinnayian, A.M.; et al. Clinical outcomes in cyclin-dependent kinase 12 mutant advanced prostate cancer. Eur. Urol. 2020, 77, 333–341, doi:10.1016/j.eururo.2019.09.036.

42. Fusco, N.; Geyer, F.C.; De Filippo, M.R.; Martelotto, L.G.; Ng, C.K.Y.; Piscuoglio, S.; Guerini-Rocco, E.; Schultheiss, A.M.; Führmann, L.; Wang, L.; et al. Genetic events in the progression of adenoid cystic carcinoma of the breast to high-grade triple-negative breast cancer. Mod. Pathol. 2016, 29, 1292–1305, doi:10.1038/modpathol.2016.134.
Cancers 2021, 13, 2930

Popova, T.; Maniè, E.; Boeva, V.; Battistella, A.; Goundiam, O.; Smith, N.K.; Mueller, C.R.; Raynal, V.; Mariani, O.; Sastre-Garau, X.; et al. Ovarian cancers harboring inactivating mutations in CDK12 display a distinct genomic instability pattern characterized by large tandem duplications. Cancer Res. 2016, 76, 1882–1891, doi:10.1158/0008-5472.CAN-15-2128.

Bell, D.; Berchuck, A.; Birrer, M.; Chien, J.; Cramer, D.W.; Dao, F.; Dhir, R.; DiSaia, P.; Gabra, H.; Glenn, P.; et al. Integrated genomic analyses of ovarian carcinoma. Nature 2011, 474, 609–615, doi:10.1038/nature10166.

Naidoo, K.; Wai, P.T.; Maguire, S.L.; Daley, F.; Haider, S.; Kriplani, D.; Campbell, J.; Mirza, H.; Grigoriadis, A.; Tutt, A.; et al. Evaluation of CDK12 expression as a potential novel biomarker for DNA damage response-targeted therapies in breast cancer. Mol. Cancer Ther. 2018, 17, 306–315, doi:10.1158/1535-7163.MCT-17-0760.

Ekumi, K.M.; Paculova, H.; Lenasi, T.; Pospichalova, V.; Böskén, C.A.; Rybarikova, J.; Bryja, V.; Geyer, M.; Blazek, D.; Barборic, M. Ovarian carcinoma CDK12 mutations misregulate expression of DNA repair genes via deficient formation and function of the CDk12/CycK complex. Nucleic Acids Res. 2015, 43, 2575–2589, doi:10.1093/nar/gkt101.

Lui, G.Y.L.; Grandori, C.; Kemp, C.J. CDK12: An emerging therapeutic target for cancer. J. Clin. Pathol. 2018, 71, 957–962, doi:10.1136/jclinpath-2018-205356.

Johnson, S.F.; Cruz, C.; Greifenhagen, A.K.; Dust, S.; Stover, D.G.; Chi, D.; Primack, B.; Cao, S.; Bernhardy, A.J.; Coulson, R.; et al. CDK12 inhibition reverses de novo and acquired PARP inhibitor resistance in BRCA wild-type and mutated models of triple-negative breast cancer. Cell Rep. 2016, 17, 2367–2381, doi:10.1016/j.celrep.2016.10.077.

Baldwin, P.; Orriols, A.; Srividhar, S. Abstract 3642: Combination Nanotherapy Using the PARP Inhibitor Talazoparib and Cyclin Dependent Kinase Inhibitor Dinaciclib. Mol. Cancer Ther. 2018, CT047, doi:10.1158/1538-7445.AM2017-CT047.

Bindra, R.S.; Glazer, P.M. Repression of RAD51 gene expression by E2F4/P130 complexes in hypoxia. Cell Growth Differ. 1994, 5, 321–330, doi:10.1042/960718.

Ikeda, M.A.; Jakoi, L.; Nevin, J.R. Distinct mechanisms control the accumulation of the Rb-Related P107 and P103 proteins during cell growth. Cell Growth Differ. 1998, 9, 297–303.

Suzuki, T.; Yasui, W.; Yokozaki, H.; Naka, K.; Ishikawa, T.; Tahara, E. Expression of the E2F Family in human gastrointestinal carcinomas. Int. J. Cancer 2002, 93, 3215–3220, doi:10.1002/ijc.1121.

Gorgouli, V.G.; Zacharatos, P.; Mariatos, G.; Kotsinas, A.; Bouda, M.; Kletzas, D.; Asimacopoulos, P.J.; Agrantis, N.; Kittas, C.; Papavassiliou, A.G. Transcription factor E2F-1 acts as a growth-promoting factor and is associated with adverse prognosis in non-small cell lung carcinomas. J. Pathol. 2002, 198, 142–156, doi:10.1002/path.1211.

Clements, K.E.; Thakar, T.; Nicolae, C.M.; Liang, X.; Wang, H.-G.; Moldovan, G.-L. Loss of E2F7 confers resistance to poly-ADP-ribose polymerase (PARP) inhibitors in BRCA2-deficient cells. Nucleic Acids Res. 2016, 46, 8898–8907, doi:10.1093/nar/gkw218.

Fagan, R.; Flint, K.J.; Jones, N. Phosphorylation of E2F-1 modulates its interaction with the retinoblastoma gene product and the adenosine E4 19 KDa protein. Cell 1994, 78, 799–811, doi:10.1016/0092-8674(94)90522-3.

Martínez-Balbás, M.A.; Bauer, U.M.; Nielsen, S.J.; Brehm, A.; Kouzarides, T. Regulation of E2F1 activity by acetylation. EMBO J. 2000, 19, 662–671, doi:10.1093/emboj/19.4.662.

Choi, E.-H.; Kim, K.P. E2F1 facilitates DNA break repair by localizing to break sites and enhancing the expression of homologous recombination factors. Exp. Mol. Med. 2019, 51, 1–12, doi:10.1038/s12276-019-0307-2.

Yang, S.-Z.; Lin, F.-T.; Lin, W.-C. MCPH1/BRIT1 Cooperates with E2F1 in the activation of checkpoint, DNA repair and apoptosis. EMBO Rep. 2008, 9, 907–915, doi:10.1038/emborep.2008.128.

Bindra, R.S.; Glazer, P.M. Repression of RAD51 gene expression by E2F4/P130 complexes in hypoxia. Oncogene 2007, 26, 2048–2057, doi:10.1038/sj.onc.1210001.

Mitvelena, J.; Apraiz, A.; Vallejo-Rodríguez, J.; García-Santisteban, I.; Fullaondo, A.; Alvarez-Fernández, M.; Malumbres, M.; Zubia, A. An E2F7-dependent transcriptional program modulates DNA damage repair and genomic stability. Nucleic Acids Res. 2018, 46, 4546–4559, doi:10.1093/nar/gky218.

Clements, K.E.; Tkach, T.; Nicolae, C.M.; Liang, X.; Wang, H.-G.; Moldovan, G.-L. Loss of E2F7 confers resistance to poly-ADP-ribose polymerase (PARP) inhibitors in BRCA2-deficient cells. Nucleic Acids Res. 2018, 46, 8898–8907, doi:10.1093/nar/gkw657.

Fagan, R.; Flint, K.J.; Jones, N. Phosphorylation of E2F-1 modulates its interaction with the retinoblastoma gene product and the adenosine E4 19 KDa protein. Cell 1994, 78, 799–811, doi:10.1016/0092-8674(94)90522-3.

Martínez-Balbás, M.A.; Bauer, U.M.; Nielsen, S.J.; Brehm, A.; Kouzarides, T. Regulation of E2F1 activity by acetylation. EMBO J. 2000, 19, 662–671, doi:10.1093/emboj/19.4.662.

Zhang, N.; Wu, X.; Yang, L.; Xiao, F.; Zhang, H.; Zhou, A.; Huang, Z.; Huang, S. FoxM1 Inhibition sensitizes resistant glioblastoma cells to temozolomide by downregulating the expression of DNA repair gene Rad51. Clin. Cancer Res. 2012, 18, 9661–9671, doi:10.1158/1078-0432.CCR-12-0399.

Hine, C.M.; Li, H.; Xie, L.; Mao, Z.; Seluanov, A.; Gorbunova, V. Regulation of Rad51 promoter. Cell Cycle 2014, 13, 2038–2045, doi:10.4161/cc.29016.

Arias-Lopez, C.; Lazarro-Trueba, I.; Kerr, P.; Lord, C.J.; Dexter, T.; Iravani, M.; Ashworth, A.; Silva, A. P53 Modulates homologous recombination by transcriptional regulation of the RAD51 gene. EMBO Rep. 2006, 7, 219–224, doi:10.1038/sj.emboj.7400587.

Taniguchi, Y. The bromodomain and extra-terminal domain (BET) family: Functional anatomy of BET paralogous proteins. Int. J. Mol. Sci. 2016, 17, 1849, doi:10.3390/ijms17111849.

Wu, S.-Y.; Chiang, C.-M. The Double Bromodomain-Containing Chromatin Adaptor Brd4 and Transcriptional Regulation. J. Biol. Chem. 2007, 282, 13141–13145, doi:10.1074/jbc.R700001200.
91. Zeng, L.; Zhou, M.M. Bromodomain: An acetyl-lysine binding domain. FEBS Lett. 2002, 513, 124–128, doi:10.1016/s0014-5793(01)03309-9.

92. Yang, Z.; He, N.; Zhou, Q. Brd4 recruits P-TEFb to chromosomes at late mitosis to promote G1 gene expression and cell cycle progression. Mol. Cell Biol. 2008, 28, 967–976, doi:10.1128/MCB.01202-07.

93. Di Micco, R.; Fontanals-Cirera, B.; Low, V.; Ntzioschristos, P.; Yuen, S.K.; Lovell, C.D.; Dolgalev, I.; Yonekubo, Y.; Zhang, G.; Rusinova, E.; et al. Control of embryonic stem cell identity by BRD4-dependent transcriptional elongation of super-enhancer-associated pluripotency genes. Cell Rep. 2019, 24, 234–247, doi:10.1016/j.celrep.2014.08.055.

94. Karakashev, S.; Zhu, H.; Yokoyama, Y.; Zhao, B.; Fathkhuutdinov, N.; Kossenkov, A.V.; Wilson, A.J.; Simpkins, F.; Speicher, D.; Khabele, D.; et al. BET bromodomain inhibition synergizes with PARP inhibitor in epithelial ovarian cancer. Cell Rep. 2017, 21, 3398–3405, doi:10.1016/j.celrep.2017.11.095.

95. Mio, C.; Gerratana, L.; Bolis, M.; Caponnetto, F.; Zanello, A.; Barbina, M.; Di Loreto, C.; Garat, P.; et al. BET bromodomain inhibition synergizes with PARP inhibitor in epithelial ovarian cancer. Cancer Res. 2019, 79, 755–766, doi:10.1158/0008-5472.can-18-0223.

96. Yang, Z.; He, N.; Zhou, Q. Brd4 recruits P-TEFb to chromosomes at late mitosis to promote G1 gene expression and cell cycle progression. Mol. Cell Biol. 2008, 28, 967–976, doi:10.1128/MCB.01202-07.

97. Di Micco, R.; Fontanals-Cirera, B.; Low, V.; Ntzioschristos, P.; Yuen, S.K.; Lovell, C.D.; Dolgalev, I.; Yonekubo, Y.; Zhang, G.; Rusinova, E.; et al. Control of embryonic stem cell identity by BRD4-dependent transcriptional elongation of super-enhancer-associated pluripotency genes. Cell Rep. 2019, 24, 234–247, doi:10.1016/j.celrep.2014.08.055.

98. Karakashev, S.; Zhu, H.; Yokoyama, Y.; Zhao, B.; Fathkhuutdinov, N.; Kossenkov, A.V.; Wilson, A.J.; Simpkins, F.; Speicher, D.; Khabele, D.; et al. BET bromodomain inhibition synergizes with PARP inhibitor in epithelial ovarian cancer. Cell Rep. 2017, 21, 3398–3405, doi:10.1016/j.celrep.2017.11.095.

99. Mio, C.; Gerratana, L.; Bolis, M.; Caponnetto, F.; Zanello, A.; Barbina, M.; Di Loreto, C.; Garat, P.; et al. BET bromodomain inhibition synergizes with PARP inhibitor in epithelial ovarian cancer. Cancer Res. 2019, 79, 755–766, doi:10.1158/0008-5472.can-18-0223.
Cancers 2021, 13, 2930

92. Qiu, Z.; Oleinick, N.L.; Zhang, J. ATR/CHK1 inhibitors and cancer therapy. *Radiother. Oncol.* **2018**, *126*, 450–464, doi:10.1016/j.radonc.2017.09.043.
93. Luo, K.; Li, L.; Li, Y.; Wu, C.; Yin, Y.; Chen, Y.; Deng, M.; Nowsheen, S.; Yuan, J.; Lou, Z. A phosphorylation–deubiquitination cascade regulates the BRCA2–RAD51 axis in homologous recombination. *Genes Dev.* **2016**, *30*, 2581–2595, doi:10.1101/gad.289439.116.
94. Osman, F.; Dixon, J.; Barr, A.R.; Whitby, M.C. The f-box DNA helicase Fbh1 prevents Rhp51-dependent recombination without mediator proteins. *Mol. Cell. Biol.* **2005**, *25*, 8084–8096, doi:10.1128/MCB.25.18.8084-8096.2005.
95. Sakaguchi, C.; Morishita, T.; Shinagawa, H.; Hishida, T. Essential and distinct roles of the f-box and helicase domains of Fbh1 in DNA damage repair. *BMC Mol. Biol.* **2009**, *9*, 27, doi:10.1186/1471-2999-9-27.
96. Fugger, K.; Mistrik, M.; Danielsen, J.R.; Dinant, C.; Falck, J.; Bartek, J.; Lukas, J.; Maitland, N. Human Fbh1 helicase contributes to genome maintenance via pro- and anti-recombination activities. *J. Cell Biol.* **2009**, *186*, 655–663, doi:10.1083/jcb.200812138.
97. Lorenz, A.; Osman, F.; Folkyte, V.; Sofueva, S.; Whitby, M.C. Fbh1 limits Rad51-dependent recombination at blocked replication forks. *Mol. Cell. Biol.* **2009**, *29*, 4742–4756, doi:10.1128/MCB.00471-09.
98. Simandlová, J.; Zagelbaum, J.; Payne, M.J.; Chu, W.K.; Shevlev, I.; Hanada, K.; Chatterjee, S.; Reid, D.A.; Liu, Y.; Janscak, P.; et al. Fbh1 helicase disrupts RAD51 filaments in vitro and modulates homologous recombination in mammalian cells. *J. Biol. Chem.* **2013**, *288*, 34168–34180, doi:10.1074/jbc.M113.484493.
99. Marzio, A.; Pucinni, K.; Kwon, Y.; Maverakis, N.K.; Arbini, A.; Sung, P.; Bar-Sagi, D.; Pagano, M. The f-box domain-dependent activity of EMI1 regulates PARP sensitivity in triple-negative breast cancers. *Cell Mol. Biol.* **2019**, *73*, 224–237.e6, doi:10.1016/j.cellmolbio.2018.11.003.
100. Gong, Z.; Chen, J. E3 ligase RFWD3 participates in replication checkpoint control. *J. Biol. Chem.* **2011**, *286*, 22308–22313, doi:10.1074/jbc.M110.122286.
101. Liu, S.; Chu, J.; Yucee, N.; Leng, M.; Wang, S.-Y.; Chen, B.P.C.; Hittelman, W.N.; Wang, Y. RING finger and WD repeat domain 3 (RFWD3) associates with replication protein a (RPA) and facilitates RPA-mediated DNA damage response. *J. Biol. Chem.* **2011**, *286*, 22314–22322, doi:10.1074/jbc.M111.222802.
102. Inano, S.; Sato, K.; Katsuki, Y.; Kobayashi, W.; Tanaka, H.; Nakajima, K.; Nakada, S.; Miyoshi, H.; Knie, S.; Takaori-Kondo, A.; et al. RFWD3-mediated ubiquitination promotes timely removal of both RPA and RAD51 from DNA damage sites to facilitate homologous recombination. *Mol. Cell Biol.* **2017**, *66*, 622–634.e8, doi:10.1007/molcel.2017.04.022.
103. Nascon, J.; Krais, J.J.; Bernhardy, A.J.; Clausen, E.; Feng, W.; Wang, Y.; Nicolas, E.; Cai, K.Q.; Tricarico, R.; Hua, X.; et al. BRCA1 mutation-specific responses to 53BP1 loss-induced homologous recombination and PARP inhibitor resistance. *Cell Rep.* **2018**, *25*, 1384, doi:10.1016/j.celrep.2018.10.009.
104. Ahlskog, J.K.; Larsen, B.D.; Achanta, K.; Sørensen, C.S. ATM/ATR-mediated phosphorylation of PALB2 promotes RAD51 function. *EMBO Rep.* **2016**, *17*, 671–681, doi:10.15252/embr.201541435.
105. Buisson, R.; Joshi, N.; Rodrigue, A.; Ho, C.K.; Kreuzer, J.; Foo, T.K.; Hardy, E.J.L.; Dellaire, G.; Haas, W.; Xia, B.; et al. Coupling of homologous recombination and the checkpoint by ATR. *Mol. Cell Biol.* **2017**, *65*, 336–346, doi:10.1128/mcb.2016.12.007.
106. Yazinski, S.A.; Comaills, V.; Buisson, R.; Geneo, M.-M.; Nguyen, H.D.; Ho, C.K.; Kwan, T.T.; Morris, R.; Laufer, S.; Nussenzwieg, A.; et al. ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP-dependent BRCA-deficient cancer cells. *Genes Dev.* **2017**, *31*, 318–332, doi:10.1101/gad.290957.116.
107. Luijsterburg, M.S.; Typas, D.; Caron, M.C.; Wiegant, W.W.; van den Heuvel, D.; Boonen, R.A.; Couturier, A.M.; Mullenders, L.H.; Masson, J.-Y.; van Attikum, H. A PALB2-interacting domain in RNF168 couples homologous recombination to DNA break-induced chromatin ubiquitination. *elife* **2017**, *6*, e20922, doi:10.7554/elife.20922.
108. Lin, Z.; Kong, H.; Nei, M.; Ma, H. Origins and evolution of the Rcc8/RAD51 gene family: Evidence for ancient gene duplication and endosymbiotic gene transfer. *Proc. Natl. Acad. Sci. USA* **2006**, *103*, 10328–10333, doi:10.1073/pnas.0604232103.
109. Thacker, J. A surfeit of RAD51-like genes? *Trends Genet.* **1999**, *15*, 166–168, doi:10.1016/s0168-9525(99)01733-3.
110. Liu, N.; Lamerdin, J.E.; Tebbs, R.S.; Schild, D.; Tucker, J.D.; Shen, M.R.; Brookman, K.W.; Siciliano, M.J.; Walter, C.A.; Fan, W.; et al. XRCC2 and XRCC3, new human Rad51-family members, promote chromosome stability and protect against DNA cross-links and other damages. *Mol. Cell* **1998**, *1*, 783–793, doi:10.1016/S1097-2765(00)80078-7.
111. Sung, P. Yeast Rad55 and Rad57 proteins form a heterodimer that functions with replication protein a to promote DNA strand exchange by Rad51 recombinase. *Genes Dev.* **1997**, *11*, 1111–1121, doi:10.1101/gad.11.9.1111.
112. Takata, M.; Sasaki, M.S.; Sonoda, E.; Fukushima, T.; Morrison, C.; Albala, J.S.; Swagemakers, S.M.A.; Kanaar, R.; Thompson, L.H.; Takeda, S. The Rad51 paralog Rad51B promotes homologous recombination repair. *Mol. Cell Biol.* **2000**, *20*, 6476–6482.
113. Takata, M.; Sasaki, M.S.; Tachiri, S.; Fukushima, T.; Sonoda, E.; Schild, D.; Thompson, L.H.; Takeda, S. Chromosome instability and defective recombinational repair in the five Rad51 paralogs. *Mol. Cell Biol.* **2001**, *21*, 2858–2866, doi:10.1128/MCB.21.8.2858-2866.2001.
114. Fuller, L.F.; Painter, R.B. A Chinese hamster ovary cell line hypersensitive to ionizing radiation and deficient in repair replication. *Mutat. Res. DNA Repair Rep.* **1988**, *193*, 109–121, doi:10.1016/0167-8817(88)90041-7.
115. Rivera, B.; Di Iorio, M.; Frankum, J.; Nadaf, J.; Fahiminiya, S.; Arcand, S.L.; Burk, D.L.; Grapton, D.; Tomiak, E.; Hastings, V.; et al. Functionally Null RAD51D Missense Mutation Associates Strongly with Ovarian Carcinoma. *Cancer Res.* **2017**, *77*, 4517–4529, doi:10.1158/0008-5472.CAN-17-0190.
116. Park, D.J.; Lesueur, F.; Nguyen-Dumont, T.; Pertesi, M.; Odefrey, F.; Hammet, F.; Neuhause, S.L.; John, E.M.; Andrulis, I.L.; Terry, M.B.; et al. Rare mutations in XRCC2 increase the risk of breast cancer. *Am. J. Hum. Genet.* 2012, 90, 734–739, doi:10.1016/j.ajhg.2012.02.027.

117. Loveday, C.; Turnbull, C.; Ruark, E.; Nicola, R.M.M.; Ramsay, E.; Hughes, D.; Warren-Perry, M.; Snape, K.; Breast Cancer Susceptibility Collaboration (UK); Eccles, D.; et al. Germline RAD51C mutations confer susceptibility to ovarian cancer. *Nat. Genet.* 2012, 44, 475–476, doi:10.1038/ng.2224.

118. Hu, C.; Hart, S.N.; Gnanaoliu, R.; Huang, H.; Lee, K.Y.; Na, J.; Gao, C.; Lylequist, J.; Yadav, S.; Boddicker, N.J.; et al. A population-based study of genes previously implicated in breast cancer. *Nat. Engl. J. Med.* 2021, 384, 440–451, doi:10.1056/NEJMoa2005936.

119. Felicio, P.S.; Grasel, R.S.; Campacci, N.; de Paula, A.E.; Galvão, H.C.R.; Torrezan, G.T.; Sabato, C.; et al. Whole-exome sequencing of Non-BRCA1/BRCA2 mutation carrier cases at high-risk for hereditary breast/ovarian cancer. *Hum. Mutat.* 2021, 42, 290–299, doi:10.1002/humu.24158.

120. Sanoguera-Miralles, L.; Valenzuela-Palomos, A.; Bueno-Martínez, E.; Llovet, P.; Diez-Gómez, B.; Caloca, M.J.; Pérez-Segura, P.; Fraile-Bethencourt, E.; Colmena, M.; Carvalho, S.; et al. Comprehensive functional characterization and clinical interpretation of 20 splice-site variants of the RAD51C gene. *Cancers (Basel)* 2020, 12, 3771, doi:10.3390/cancers12123771.

121. Masson, J.Y.; Tarsounas, M.C.; Stasiak, A.Z.; Stasiak, A.; Shah, R.; Mcllrath, M.J.; Benson, F.E.; West, S.C. Identification and purification of two distinct complexes containing the five RAD51 paralogs. *Genes Dev.* 2001, 15, 3296–3307, doi:10.1101/gad.947001.

122. Masson, J.-Y.; Stasiak, A.Z.; Stasiak, A.; Benson, F.E.; West, S.C. Complex formation by the human RAD51C and XRCC3 recombination repair proteins. *Proc. Natl. Acad. Sci. USA* 2001, 98, 8440–8446, doi:10.1073/pnas.11005698.

123. Yonetani, Y.; Hochegger, H.; Sonoda, E.; Shinya, S.; Yoshikawa, H.; Takeda, S.; Yamazoe, M. Differential and collaborative actions of Rad51 paralog proteins in cellular response to DNA damage. *Nucleic Acids Res.* 2005, 33, 4544–4552, doi:10.1093/nar/gki766.

124. Shor, E.; Weinstein, J.; Rothstein, R. A Genetic screen for top3 suppressors in saccharomyces cerevisiae identifies SHU1, SHU2, PSY3 and CSM2: Four genes involved in error-free DNA repair. *Genetics* 2005, 169, 1275–1289, doi:10.1534/genetics.104.036764.

125. Liu, T.; Wan, L.; Wu, Y.; Chen, J.; Huang, J. HSWS1-SWSAP1 is an evolutionarily conserved complex required for efficient homologous recombination repair. *J. Biol. Chem.* 2011, 286, 41758–41766, doi:10.1074/jbc.M111.271080.

126. Martin, V.; Chahwan, C.; Gao, H.; Blais, V.; Wohlschlegel, J.; Yates, J.R.; McGowan, C.H.; Russell, P.; Sws1 is a conserved regulator of homologous recombination in eukaryotic cells. *EMBO J.* 2006, 25, 2564–2574, doi:10.1038/sj.emboj.7601141.

127. Garin, E.B.; Gon, S.; Sullivan, M.R.; Brunette, G.J.; Gian, A.D.; Concordet, J.-P.; Giovannangeli, C.; Dirks, W.G.; Eberth, S.; Bernstein, K.A.; et al. Differential requirements for the RAD51 paralogs in genome repair and maintenance in human cells. *PloS Genet.* 2019, 15, e1008355, doi:10.1371/journal.pgen.1008355.

128. Chun, J.; Buechelmaier, E.S.; Powell, S.N. Rad51 paralog complexes BCDX2 and CX3 act at different stages in the BRCA1-BRCA2-dependent homologous recombination pathway. *Mol. Cell. Biol.* 2013, 33, 387–395, doi:10.1128/MCB.00465-12.

129. Ball, L.G.; Zhang, K.; Cobb, J.A.; Boone, C.; Xiao, W. The Yeast Shu complex couples error-free post-replication repair to homologous recombination. *Mol. Microbiol.* 2009, 73, 89–102, doi:10.1111/j.1365-2958.2009.06748.x.

130. Godin, S.; Wier, A.; Kabbinavar, F.; Bratton-Palmer, D.S.; Ghodke, H.; Van Houten, B.; VanDemark, A.P.; Bernstein, K.A. The Shu complex interacts with Rad51 through the Rad51 paralogues Rad53-Rad57 to mediate error-free recombination. *Nucleic Acids Res.* 2013, 41, 4525–4534, doi:10.1093/nar/gkt138.

131. Godin, S.K.; Zhang, Z.; Herken, B.W.; Westmoreland, J.W.; Lee, A.G.; Mihalevic, M.J.; Yu, Z.; Sobol, R.W.; Resnick, M.A.; Bernstein, K.A. The Shu complex promotes error-free tolerance of alkylation-induced base excision repair products. *Nucleic Acids Res.* 2016, 44, 8199–8215, doi:10.1093/nar/gkw355.

132. Moldovan, G.-L.; Dejusphong, D.; Petalcin, M.I.R.; Hofmann, K.; Takeda, S.; Boulton, S.J.; D’Andrea, A.D. Inhibition of homologous recombination by the PCNA-interacting protein PARI. *Mol. Cell* 2012, 45, 75–86, doi:10.1016/j.molcel.2011.11.010.

133. Wu, L.; Davies, S.L.; Levitt, N.C.; Hickson, I.D. Potential role for the BLM Helicase in recombinational repair via a conserved interaction with RAD51. *J. Biol. Chem.* 2001, 276, 19375–19381, doi:10.1074/jbc.M009471200.

134. Huang, F.; Motlekar, N.A.; Burgwin, C.M.; Napper, A.P.; Diamond, S.L.; Mazin, A.V. Identification of specific inhibitors of human RAD51 recombinaise using high-throughput screening. *ACS Chem. Biol.* 2011, 6, 628–635, doi:10.1021/cb100428c.

135. Huang, F.; Mazina, O.M.; Zentner, I.J.; Cocklin, S.; Mazin, A.V. Inhibition of homologous recombination in human cells by targeting RAD51 recombinaise. *J. Med. Chem.* 2012, 55, 3011–3020, doi:10.1021/jm201173g.

136. Huang, F.; Mazin, A.V. A small molecule inhibitor of human RAD51 potentiates breast cancer cell killing by therapeutic agents in mouse xenografts. *PloS ONE* 2014, 9, e100993, doi:10.1371/journal.pone.0100993.

137. Ward, A.; Dong, L.; Harris, J.M.; Khanna, K.K.; Al-Ejeh, F.; Fairlie, D.P.; Wiegman, A.P.; Liu, L. Quinazolinone derivatives as inhibitors of homologous recombinaise RAD51. *Bioorganic Med. Chem. Lett.* 2017, 27, 3096–3100, doi:10.1016/j.bmcl.2017.05.039.

138. Budke, B.; Logan, H.L.; Kalin, J.H.; Zelivianskaia, A.S.; Cameron McGuire, W.; Miller, L.L.; Stark, J.M.; Kozikowski, A.P.; Bishop, D.K.; Connell, P.P. RI-1: A chemical inhibitor of RAD51 that disrupts homologous recombination in human cells. *Nucleic Acids Res.* 2012, 40, 7347–7357, doi:10.1093/nkds353.

139. Budke, B.; Kalin, J.H.; Pawlowski, M.; Zelivianskaia, A.S.; Wu, M.; Kozikowski, A.P.; Connell, P.P. An optimized RAD51 inhibitor that disrupts homologous recombination without requiring michael acceptor reactivity. *J. Med. Chem.* 2013, 56, 254–263, doi:10.1021/jm301565b.
140. Zhu, J.; Zhou, L.; Wu, G.; Konig, H.; Lin, X.; Li, G.; Qiu, X.-L.; Chen, C.-F.; Hu, C.-M.; Goldblatt, E.; et al. A novel small molecule RAD51 inactivator overcomes imatinib-resistance in chronic myeloid leukaemia. *EMBO Mol. Med.* 2013, 5, 353–365, doi:10.1002/emmm.201201760.

141. Zhu, J.; Chen, H.; Guo, X.E.; Qiu, X.-L.; Hu, C.-M.; Chamberlin, A.R.; Lee, W.-H. Synthesis, molecular modeling, and biological evaluation of novel RAD51 inhibitors. *Eur. J. Med. Chem.* 2015, 96, 196–208, doi:10.1016/j.ejmech.2015.04.021.

142. Guy, J.L.; Maclay, T.; Day, M.; Burness, M.L.; Mills, K. Abstract P2-05-05: RAD51 Inhibition Using CYT-0851, Shows Anti-Cancer Activity in Cellular Models of Breast Cancer and Acts Synergistically with PARP Inhibitors. *Cancer Res* 2020, 80, P2-05-05, doi:10.1158/1538-7445.SABCS19-P2-05-05.

143. Saeki, H.; Jogo, T.; Kawazoe, T.; Kamori, T.; Nakaji, Y.; Zaitsu, Y.; Fujiwara, M.; Baba, Y.; Nakamura, T.; Iwata, N.; et al. RAD51 expression as a biomarker to predict efficacy of preoperative therapy and survival for esophageal squamous cell carcinoma: A large-cohort observational study (KSCC1307). *Ann. Surg.* 2020, Publish Ahead of Print, doi:10.1097/SLA.0000000000003975.

144. Pataer, A.; Shao, R.; Correa, A.M.; Behrens, C.; Roth, J.A.; Vaporiyan, A.A.; Wistuba, I.I.; Swisher, S.G. Major pathologic response and RAD51 predict survival in lung cancer patients receiving neoadjuvant chemotherapy. *Cancer Med.* 2018, 7, 2405–2414, doi:10.1002/cam4.1505.

145. Cruz, C.; Castroviejo-Bermejo, M.; Gutiérrez-Enríquez, S.; Llop-Guevara, A.; Ibrahim, Y.H.; Gris-Oliver, A.; Bonache, S.; Morancho, B.; Bruna, A.; Rueda, O.M.; et al. RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer. *Ann. Oncol.* 2018, 29, 1203–1210, doi:10.1093/annonc/mdy099.

146. Lindemann, A.; Patel, A.A.; Tang, L.; Tanaka, N.; Gleber-Netto, F.O.; Bartels, M.D.; Wang, L.; McGrail, D.J.; Lin, S.-Y.; Frank, S.J.; et al. Combined inhibition of Rad51 and Wee1 enhances cell killing in HNSCC through induction of apoptosis associated with excessive DNA damage and replication stress. *Mol. Cancer Ther.* 2021, Online ahead of print. 1535-7163.MCT-20-0252, doi:10.1158/1535-7163.MCT-20-0252.

147. Aubry, A.; Pearson, J.D.; Huang, K.; Livne-bar, I; Ahmad, M.; Jagadeesan, M.; Khetan, V.; Ketela, T.; Brown, K.R.; Yu, T.; et al. Functional genomics identifies new synergistic therapies for retinoblastoma. *Oncogene* 2020, 39, 5338–5357, doi:10.1038/s41388-020-1372-7.